This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best cheap dividend stocks to buy right now. Value investing has remained a favored approach among ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...